Axogen, Inc.
No SEC Form 4 filings for $AXGN in the last 30 days.
Axogen (AXGN) reported Q2 2026 revenue of $69.7 million, up 23.1% year over year, driven by growth in breast, extremities, and OMF. Breast revenue grew more than 50% and contributed about two-thirds of growth. Gross margin was 72.7%. Adjusted net income was $7.3 million ($0.12/share). Full-year revenue guidance raised to at least $279 million (24% growth) and gross margin to at least 73%.
Trace Biosciences said it received a strategic investment from Axogen, Inc. (NASDAQ: AXGN) as part of Trace’s Series A financing, with additional investors expected. Trace’s Nerve Trace Dx, cleared for an IND in Dec 2025, has started Phase I. Funds will support Phase II and III trials toward an NDA, using near-infrared imaging to visualize nerves during surgery.
Axogen, Inc. (AXGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991axgnearningsreleaseda.htm EX-99.1 Q2 2026 EARNINGS PRESS RELEASE Document Exhibit 99.1 Axogen, Inc. Reports Second Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million ALACHUA and TAMPA, FL – July 29, 2026 – Axogen
Over the past 7 days, alphai's AI scored 1 news story mentioning AXGN (Axogen, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AXGN coverage spans financial news, earnings and corporate actions.
Raised revenue outlook supports upside, but gross margin guidance was lowered due to a mix shift toward longer Avance grafts with higher production costs.
Investment signals Axogen’s continued push into peripheral nerve restoration and could support sentiment around its surgical solutions ecosystem.
Guidance raise plus strong top-line growth is likely to support near-term sentiment, despite weaker gross margin and lower adjusted EBITDA.
Routine annual-meeting voting outcomes; no new financial guidance, deal terms, or enforcement action disclosed.
The recent sale of shares by Axogen's Chief Innovation Officer suggests personal portfolio management rather than company performance concerns. Analysts remain bullish with target prices between $39 and $43, and the company exceeded Q4 2025 earnings and revenue expectations.
alphai scores every news story that mentions AXGN with an AI model for sentiment and relevance, and aggregates insider trades from Axogen, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Axogen (AXGN) reported Q2 2026 revenue of $69.7 million, up 23.1% year over year, driven by growth in breast, extremities, and OMF. Breast revenue grew more than 50% and contributed about two-thirds of growth. Gross margin was 72.7%. Adjusted net income was $7.3 million ($0.12/share). Full-year revenue guidance raised to at least $279 million (24% growth) and gross margin to at least 73%.
6 min readTrace Biosciences said it received a strategic investment from Axogen, Inc. (NASDAQ: AXGN) as part of Trace’s Series A financing, with additional investors expected. Trace’s Nerve Trace Dx, cleared for an IND in Dec 2025, has started Phase I. Funds will support Phase II and III trials toward an NDA, using near-infrared imaging to visualize nerves during surgery.
3 min readAxogen, Inc. (AXGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991axgnearningsreleaseda.htm EX-99.1 Q2 2026 EARNINGS PRESS RELEASE Document Exhibit 99.1 Axogen, Inc. Reports Second Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million ALACHUA and TAMPA, FL – July 29, 2026 – Axogen
3 min readAxogen, Inc. (AXGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. axgn-20260623 0000805928 false 0000805928 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readAxogen's Chief Innovation Officer, Erick Wayne DeVinney, sold 5,221 shares of common stock for approximately $171,457 and disposed of 2,870 shares to cover tax obligations. Despite the stock's recent retreat, analysts maintain a bullish outlook with price targets between $39 and $43. The company also recently surpassed Q4 2025 earnings and revenue expectations.
3 min readAxogen (AXGN) reported strong 21% revenue growth for Q4 2025, but missed EPS expectations, leading to an 8% share decline and highlighting margin pressures. The company is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Despite a hold rating due to a stretched valuation, the company anticipates normalization of gross margin compression as biologics pricing and payer coverage expand.
3 min readU.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Caterpillar Inc ( NYSE:CAT ) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results.
4 min readRaises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ...
3 min readNEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ( "Axogen" or the "Company" ) AXGN. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
2 min readHere is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
3 min read
